New expertise strengthens RegenCura’s development
RegenCura strengthens its team to accelerate regulatory development and hires chemist Björn Greijer.
RegenCura strengthens its team to accelerate regulatory development and hires chemist Björn Greijer.
Nil Medical AB has received its first external investment – from Barncancerfonden Impact Invest AB, a newly established impact venture launched by the Swedish Childhood Cancer Fund.
“A perfect match for us. The mission of Barncancerfonden Impact Invest aligns perfectly with our values: ensuring that any potential profit contributes to future patient benefit and supports continued research and innovation,” says Martin Hanberger, CEO and founder of Nil Medical AB.
Nil Medical AB is currently seeking a Sales Manager to support its continued growth and international expansion. The ideal candidate will bring global experience from the medical technology sector and play a key role in building the company’s commercial organization.
The Umeå based life science company ProTest Diagnostics has secured a significant grant from the World Anti-Doping Agency (WADA) to develop cutting-edge technology aimed at detecting one of sport’s hardest-to-spot cheating methods – blood doping.
The Umeå-based Agtech innovator Cropcision has successfully closed a seed funding round, backed by Northern Light Capital (NLC) and Partnerinvest Norr. The company is scaling up its capacity to deliver plastic-free, controlled-release fertilizers that align with upcoming EU regulations and meet the growing global demand for sustainable and affordable solutions.
Growing demand for the Nil Medical Vestpack has prompted Umeå-based Nil Medical AB to expand its leadership team. Malin Walfridsson, former Head of R&D at Nordic Biomarker, has joined the company as COO and Deputy CEO.
Omnio AB, a Umeå-based biotech company focused on innovative treatments for chronic wounds, has secured a major capital injection from current shareholders.
“This support allows us to complete our GMP manufacturing process and move toward clinical trials,” says newly appointed CEO, Felipe Velasquez.
Are you a chemist with a university degree? RegenCura is now hiring to accelerate chemical synthesis and validation testing in their regulatory development work.
Northern Sweden’s only dedicated lab fair is back — and bigger than before. On May 8, Umeå Lab Fair returns to Tvistevägen 48A, bringing together 20 companies under one roof.
“There’s clearly a strong demand — companies have been lining up to take part,” says Christin Grundström, Lab and Community Manager at Umeå Biotech Incubator (UBI).
Umeå-based biotech company Vakona has raised new capital from a combination of existing shareholders and four new private investors. The funds will enable the company to complete the process development of its innovative active substance as it moves toward the clinical phase.
The innovative patch M045A, developed by Mucocort for the treatment of Recurrent Aphthous Stomatitis (commonly known as canker sores), has reached an important milestone with the filing of a new patent application. This latest application focuses specifically on the patch’s unique antimicrobial effect, further strengthening the technology’s intellectual property portfolio.
The Moss Man Daniel Pacurar was part of a Swedish business delegation that visited Thailand, Vietnam and Malaysia. Daniel is part of Umeå Biotech Incubator with Boreal Orchards and the re:moss project, and we contacted Daniel to learn more about the trip.
Roger Folkhage has been appointed as the new CEO of the Umeå-based company Medicvent. He joins from his previous role as Global Sales Director at Bohus Biotech.
Umeå Biotech Incubator (UBI) has been awarded 2.5 million SEK in continued support from Kempestiftelserna for 2026. These funds are designated to assist verification activities for researchers and projects associated with UBI.
Nil Medical’s medical infusion vest, the “Nil Medical Vestpack,” is being tested at five hospitals in Sweden as part of a clinical trial. Now, the company is looking to hire a Business & Sales Manager.
“To achieve our goal of making the vest available to more children and hospitals, we need to grow our team,” says Martin Hanberger, CEO and founder of Nil Medical.
Just weeks after being granted a patent in Australia, Mucocort AB has achieved yet another significant milestone — this time in Japan. The newly approved patent for its innovative mucoadhesive patch, M045A, designed for the treatment of oral aphthous ulcers, further strengthens the company’s global presence.
QureTech Bio AB has been granted a patent by the European Patent Office (EPO) for GmPcides, a new class of synthetic antibacterials.
Umeå-based LIPUM AB has announced the successful completion of their Phase I study with SOL-116, reporting positive results.
Mucocort AB has successfully developed M045A, an innovative mucoadhesive “patch” for the treatment of oral aphthous ulcers. The company has now been granted a patent in Australia for its medical technology innovation, marking a significant milestone in its international expansion.
Lina Olsson, former CEO of HiloProbe, is stepping into a new role as Business Unit Manager at the consulting firm Prevas. The company is expanding into Umeå focusing on MedTech and Life Science.